MET anticancer drugs will enter the first stage of registration of insurance benefits. According to related industries, Tabrecta will be introduced to the HIRA Cancer Disease Review Committee on August 10. Tabrecta was approved in Korea in November last year as a non-small cell Lung Cancer (NSCLC) treatment that confirmed MET Exxon 14 deficiency as the first MET inhibitor. MET mutations are a rare type that accounts for about 3% to 4% of metastatic non-small cell lung cancer, and as there have been no treatments, interest in these new drugs is increasing.

Effectiveness was confirmed through GEOMETRY mono-1 study in 97 patients with METex14. As a result of the study, the overall response rate was 68% in